OligoNova Hub – from Ideas to Oligonucleotide Therapies

OligoNova Hub provides state-of-the-art drug discovery infrastructure and expertise to academic researchers, to support the translation of fundamental research findings into patient-benefitting therapeutic molecules. OligoNova Hub is an integrated part of the national SciLifeLab Drug Discovery and Development Platform (DDD), is organized within the Sahlgrenska Academy at the University of Gothenburg, and located in the AstraZeneca BioVenture Hub in Mölndal, Sweden.

About OligoNova OligoNova was initiated by the University of Gothenburg and AstraZeneca in 2020 through support from SweLife and the Swedish government innovation agency, Vinnova. The aim of OligoNova is to gather national experts within the area of therapeutic oligonucleotides representing academia, regions, institutes, industry and small and medium enterprises and create a national platform for research and development of therapeutic oligonucleotides.

In 2021, based on generous support from the Knut and Alice Wallenberg Foundation, Carl Bennet AB, University of Gothenburg, Västra Götalandsregionen and SciLifeLab, the national research infrastructure OligoNova Hub was formed. Part of the SciLifeLab Drug Discovery and Development platform and the Sahlgrenska Academy Core Facilities at the University of Gothenburg, OligoNova Hub helps transform groundbreaking academic research at Swedish universities into new treatments for patients.

Are you interested in OligoNova or seeking support?

Please don’t hesitate to reach out to the OligoNova team if you are affiliated with a Swedish university and have a therapeutic idea or innovation that matches the scope of OligoNova!